Acquired haemophilia A may be associated with clopidogrelBMJ 2004; 329 doi: https://doi.org/10.1136/bmj.329.7461.323 (Published 05 August 2004) Cite this as: BMJ 2004;329:323
- Montaser Haj, specialist registrar in haematology1,
- H Dasani, associate specialist in haematology1,
- S Kundu, specialist registrar in haematology1,
- U Mohite, specialist registrar in haematology1,
- P W Collins (), senior lecturer in haematology1
- Correspondence to: P W Collins
Acquired haemophilia A is a rare bleeding disorder caused by autoantibodies against factor VIII.1 Bleeding is often severe and may be life threatening. In half of patients, no underlying disorder is found, however, common associations are with autoimmune disease, malignancy, dermatological disorders, pregnancy, and drugs.1–3
Two women aged 70 and 67 presented with a history of excessive bruising and soft tissue bleeding 2-3 months after starting clopidogrel (Plavix; Bristol-Myers Squibb, Sanofi-Synthelabo) for peripheral vascular disease. Their drugs had not changed recently in any other way. They had no clinical symptoms or signs of malignancy, antiphosphpolipid syndrome, or collagen vascular disease.
One patient had had a documented normal activated partial thromboplastin time at the time of starting clopidogrel; the other had not been tested. Investigation showed that the women had a normal platelet count, peripheral blood film, and prothrombin time. Both had a prolonged activated partial thromboplastin time of 48.6 and 77.6 seconds (normal range 23-33 seconds). Tests for lupus anticoagulant, anticardiolipin antibody, antinuclear factor, double stranded DNA, and rheumatoid factor were negative. The women had low factor VIII (3.9 and 1 IU/dl) with normal von Willebrand factor levels and a detectable antifactor VIII inhibitor (2.2 and 17.6 Bethesda units). We treated both patients with 1 mg/kg of prednisolone. Concentrations of factor VIII rose to 119 and 136 IU/dl, and the inhibitor became undetectable (< 0.4 Bethesda units) within eight weeks of treatment. The factor VIII inhibitor relapsed in one patient when the steroid dose was reduced, but we induced and sustained remission with azathioprine.
A possible link between autoimmune acquired haemophilia and clopidogrel has not been previously reported. Clopidogrel has been associated with microangiopathic haemolytic anaemia and thrombocytopenia,4 5 suggesting other possible immune mediated adverse events.
Increased bruising should not be ascribed to the antiplatelet action of clopidogrel unless a platelet count and coagulation screen have been found to be normal. Investigation for an antifactor VIII inhibitor should be done if indicated by a prolonged activated partial thromboplastin time.
Competing interests None declared.